You are here

  • Home
  • Archive
  • Volume 7, Issue 9
  • Irradiation enhanced risks of hospitalised pneumonopathy in lung cancer patients: a population-based surgical cohort study

Article Text

Article menu

Download PDFPDF

XML
Oncology
Research
Irradiation enhanced risks of hospitalised pneumonopathy in lung cancer patients: a population-based surgical cohort study
  1. Shih-Kai Hung1,2,
  2. Yi-Chun Chen2,3,
  3. Wen-Yen Chiou1,2,
  4. Chun-Liang Lai2,4,
  5. Moon-Sing Lee1,2,
  6. Yuan-Chen Lo1,2,
  7. Liang-Cheng Chen1,2,
  8. Li-Wen Huang1,2,
  9. Nai-Chuan Chien2,5,
  10. Szu-Chi Li2,6,
  11. Dai-Wei Liu2,7,
  12. Feng-Chun Hsu1,
  13. Shiang-Jiun Tsai1,
  14. Michael WY Chan8,9,10,
  15. Hon-Yi Lin1,2,8
  1. 1 Department of Radiation Oncology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-Yi, Taiwan
  2. 2 School of Medicine, Tzu Chi University, Hualien, Taiwan
  3. 3 Division of Nephrology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-Yi, Taiwan
  4. 4 Chest Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-Yi, Taiwan
  5. 5 Thoracic Surgery, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-Yi, Taiwan
  6. 6 Haematology-Oncology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-Yi, Taiwan
  7. 7 Department of Radiation Oncology, Buddhist Tzu Chi General Hospital, Hualien, Taiwan
  8. 8 Institute of Molecular Biology, National Chung Cheng University, Chia-Yi, Taiwan
  9. 9 Department of Life Science, National Chung Cheng University, Chia-Yi, Taiwan
  10. 10 Human Epigenomics Centre, National Chung Cheng University, Chia-Yi, Taiwan
  1. Correspondence to Dr Hon-Yi Lin; doc16021{at}gmail.com

Abstract

Objective Pulmonary radiotherapy has been reported to increase a risk of pneumonopathy, including pneumonitis and secondary pneumonia, however evidence from population-based studies is lacking. The present study intended to explore whether postoperative irradiation increases occurrence of severe pneumonopathy in lung cancer patients.

Design, setting and participants The nationwide population-based study analysed the Taiwan National Health Insurance Research Database (covered >99% of Taiwanese) in a real-world setting. From 2000 to 2010, 4335 newly diagnosed lung cancer patients were allocated into two groups: surgery-RT (n=867) and surgery-alone (n=3468). With a ratio of 1:4, propensity score was used to match 11 baseline factors to balance groups.

Interventions/exposure(s) Irradiation was delivered to bronchial stump and mediastinum according to peer-audited guidelines.

Outcome(s)/measure(s) Hospitalised pneumonia/pneumonitis-free survival was the primary end point. Risk factors and hazard effects were secondary measures.

Results Multivariable analysis identified five independent risk factors for hospitalised pneumonopathy: elderly (>65 years), male, irradiation, chronic obstructive pulmonary disease (COPD) and chronic kidney disease (CKD). Compared with surgery-alone, a higher risk of hospitalised pneumonopathy was found in surgery-RT patients (HR, 2.20; 95% CI, 1.93–2.51; 2-year hospitalised pneumonia/pneumonitis-free survival, 85.2% vs 69.0%; both p<0.0001), especially in elderly males with COPD and CKD (HR, 13.74; 95% CI, 6.61–28.53; p<0.0001). Unexpectedly, we observed a higher risk of hospitalised pneumonopathy in younger irradiated-CKD patients (HR, 13.07; 95% CI, 5.71–29.94; p<0.0001) than that of elderly irradiated-CKD patients (HR, 4.82; 95% CI, 2.88–8.08; p<0.0001).

Conclusions A high risk of hospitalised pneumonopathy is observed in irradiated patients, especially in elderly males with COPD and CKD. For these patients, close clinical surveillance and aggressive pneumonia/pneumonitis prevention should be considered. Further investigations are required to define underlying biological mechanisms, especially for younger CKD patients.

  • lung cancer
  • pneumonia
  • pneumonitis
  • radiotherapy
  • chronic kidney disease
  • propensity score match.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

http://dx.doi.org/10.1136/bmjopen-2016-015022

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Strengths and limitations of this study

    • To our best knowledge, the present study was the first investigation to apply a population-based propensity-score-matched design to explore a risk level of hospitalised pneumonopathy in the real-world medical setting.

    • According to independent risk factors, the present study conducted a simplified sensitivity analysis to decrease unmeasured confounding effects.

    • According to independent risk factors, the present study calculated integer risk scores to stratify high-risk patients: this approach worked well.

    • Despite our efforts to decrease potential bias, this present study analysed a secondary database, which inevitably harbours some unobserved variables and may constrain the study interpretation.

    • A retrospective design of the present study also limits the conclusion. Further prospective studies should be warranted for confirming the present observation.

    Introduction

    Patients with lung cancer are frequently encountered in both primary and in-patient care, characterising high rates of mortality and morbidities.1–3 Radiotherapy is one of the major treatment modalities in managing lung cancer patients.4 However, irradiation has been reported to correlate with an increased incidence of several types of pneumonopathy, such as infectious pneumonia,5 6 non-infectious organic pneumonia7–10 and radiation pneumonitis,11–13 even after a 2-year follow-up period.14

    Clinically, differentiating radiation pneumonitis from secondary pneumonia is not easy.11 15 16 Several aetiologies have been declared. First, the radiological finding is similar between radiation pneumonitis and secondary pneumonia17 and both of them showed an increased lung infiltration and/or parenchymal consolidation.16 18 Second, no reliable tools are available to diagnose radiation pneumonitis directly, its diagnosis is largely dependent on exclusion of other pulmonary diseases.16 Third, secondary pneumonia is frequently co-occurred in patients with radiation pneumonitis, either simultaneously or sequentially.8

    Remarkably, when progressive dyspnea developed, either radiation pneumonitis or secondary infectious/non-infectious pneumonia threatens a patient’s life.12 19–21 As a result, it is crucial to identify risk factors of severe pneumonopathy that required in–patient care. In this regard, several risk factors have been recognised in association with the occurrence of pneumonia, for example, elderly male,22 chronic obstructive pulmonary disease (COPD),23 chronic kidney disease (CKD),24 thoracic surgery,25–27 chemotherapy and radiotherapy (RT).6 28 On the other hand, potential hazard factors of radiation pneumonitis have also been reported, as follows: age,29 30 gender,20 COPD,31 diabetes mellitus,32 thoracic surgery33 and chemotherapy.34 However, evidence from population-based studies is largely limited in irradiated lung cancer patients.

    Hence, the population-based study intended to explore the association between irradiation and hospitalised pneumonopathy in a lung cancer surgical cohort. We hypothesised that irradiated lung cancer patients may encounter a higher risk of hospitalised pneumonopathy (ie, severe pneumonia/pneumonitis that required in-patient care) than that of non-irradiated patients.

    Methods

    Database and ethic statement

    The present study investigated the research database of the Taiwan National Health Insurance. The major characteristic of this database is its high coverage rate of medical care in a national population (ie, >99% Taiwanese).35 Thus, results obtained from this population-based database largely represented an actual condition in a real medical world setting.

    Design and conduct of the present study were approved by the Institution Review Board (IRB) of the Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation (approved number, B10001019). As mentioned previously,35–37 the IRB waived a requirement of written informed consents because permanent de-identification was conducted by the National Health Research Institute before data analysis.36 38 39

    Study design and patient allocation

    For maximally reducing potential bias, the present study used a propensity score match to create a quasi-randomised condition before statistical analysis.36 40

    From January 2000 to December 2010, a total of 4335 newly-diagnosed early-stage lung cancer patients were recruited into two groups: the surgery-RT (n=867) and surgery-alone groups (n=3468; figure 1; table 1). The identifying process was similar to our previous report.36 Briefly, we applied the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code 162 to identify lung cancer patients (n=2 18 300). And, we used a peer-reviewed data subset (ie, the Registry File for Catastrophe Illness)38 to validate lung cancer diagnosis. Then, we excluded previously diagnosed lung cancer patients to allocate newly onset patients (n=78 723).

    Figure 1
    Figure 1

    Flow chart of patient allocation. Using a propensity score, patients in the surgery-alone group were match-paired to those patients in the surgery-RT group, with a ratio of 1:4. Eleven baseline factors were simultaneously matched for paring cases, as shown in table 1. ICD-9-CM code 162 was used to initially identify lung cancer patients. Data-coded errors were validated by using a sub-dataset of the Registry of Catastrophe Illness.

    View this table:
    Table 1

    Patient and demographic characteristics according to treatment received

    To purify the study population, several exclusion criteria were used, as follows: previous pneumonia/pneumonitis (n=21 030), distant metastases at the time of initial diagnosis (n=3130; ICD-9-CM codes, 196–199), patients who were treated with radiotherapy alone (ie, without surgery) or who had a treatment component of chemotherapy (n=49 174), unpaired cases (n=995) and data error (n=59).

    Finally, we identified 867 early-stage lung cancer patients treated with surgery and postoperative radiotherapy into the surgery-RT group.

    Propensity score match: a modern tool to create comparable groups before further statistical analysis

    Surgery itself has been reported to increase a risk of pneumonia occurrence in lung cancer patients.25 26 Thus, for a better comparison, we allocated lung cancer patients treated with surgery alone as our study controls.36 Moreover, to create a between-group comparable condition before analysis, we used a propensity score to match 11 baseline factors simultaneously41: age,29 30 42 gender,20 22 COPD,22 23 32 hypertension,43 diabetes mellitus (DM),22 32 congestive heart failure (CHF),22 liver cirrhosis (LC),22 CKD,44 coronary artery disease (CAD), hyperlipidemia and tuberculosis (TB).

    We paired 3468 patients who received surgery alone into the surgical-alone comparison group by using a match ratio of 1:4. We used callipers with a width of 0.2 of the SD of the logit for the propensity score match process, as previously recommended.45 After match, patients in the two groups were compared for further analysis (table 1).46

    Patients and treatments

    The present study wished to investigate the role of irradiation in association with hospitalised pneumonopathy (ie, severe infectious/non-infectious pneumonia and/or radiation pneumonitis) in lung cancer patients who received post-operative radiotherapy. Thus, a lung cancer surgical cohort was chosen as the study population. The main reason for this selection has been declared previously.36 Briefly, patients who were able to be treated surgically had two unique characteristics – that is, a medically operable status and technically resectable tumours.

    Similarly, to maximally reduce potential bias, we excluded patients treated with chemotherapy, as reported previously.36 Two reasons for this exclusion were: excluded patients with pathologically positive nodal disease, that is, pN1-3 in stage II-III;47 48and avoided a confounding effect of chemotherapy on pneumonia occurrence.19

    As reported previously,36 postoperatively positive surgical margin was the main indication for post-operative radiotherapy. Thus, irradiating targets were mainly focused on the bronchial stump and adjacent mediastinum, with conventional radiation doses ranging from 45 Gy to 64.8 Gy.16 36 48 49 Irradiation guidelines among different institutes were regularly audited by certified external peers of the Taiwan Cancer Centre Accreditation.36 50

    Study endpoints and measurements

    We defined hospitalised pneumonia/pneumonitis-free survival as the primary end point (ICD-9-CM codes: pneumonia, 480–486; and, radiation pneumonitis, 508).51 All pneumonia/pneumonitis-free survival was defined as the secondary endpoint.

    As mentioned above, two reasons were responsible for combining infectious/non-infectious pneumonia and radiation pneumonitis as a single study endpoint. First, radiation pneumonitis and secondary pneumonia are difficult to be differentiated clinically, especially in the modern radiotherapy era.11 15 16 Second, while severe, both of them significantly threaten the patient’s life.12 19 20 Thus, combining these two diseases as a single study end event was reasonable and suitable in secondary analysis studies, such as ours.

    Hospitalised pneumonia/pneumonitis was defined as the first admission due to pneumonia/pneumonitis after surgery. All pneumonia/pneumonitis was encoded as the first diagnosis of pneumonia/pneumonitis after surgery in either an inpatient or outpatient setting.

    Statistical analysis

    We analysed and reported data according to the CONSORT statement52 and STROBE guideline (main accordance).53 SAS (version 9.2; SAS Institute, Inc., Cary, NC, USA) and SPSS (version 12, IBM SPSS Inc., Chicago, USA)36 were used for statistical analysis, accordingly. Kaplan-Meier analysis was applied to estimate survival, and the log-rank test was performed to assess curve differences between groups. The Chi-square test was used to evaluate intergroup differences for category variables.

    Considering the time effect, Cox proportional regression54 (rather than logistic regression) was conducted to perform multivariable analysis and to estimate hazardous effects, as that of a previous report.55 Multivariable-analysis-identified risk factors were selected for further stratified/simplified sensitivity analysis.36 According to previous reports,56 57 regression coefficients of independent risk factors were converted into integer risk scores. These risk scores were subsequently applied to identify high-risk patient populations.

    According to a recommendation of the STROBE guideline,53 95% confidence intervals (95% CIs) were provided in conjunction with HRs to represent hazardous size. Two biostatisticians, that is, Shiang-Jiun Tsai (for primary analysis) and Feng-Chun Hsu (for second look), independently validated all data, as reported previously.36 A p  value of <0.05 was considered as statistically significant. 

    Results

    Study group, patient and survival

    We identified 4335 patients into the two groups: surgery-RT (n=867) and surgery-alone groups (n=3468; 1:4 match-paired; figure 1). The median follow-up time was 31.8 months (range, 0.1–136.1). Most patients were aged >65 years (n=2512, 57.9%). Male patients were predominate (n=2690; 62.1%). After propensity-score match, the two study groups were well balanced in terms of 11 baseline factors, i.e., age, gender, COPD, hypertension, diabetes, coronary artery disease, liver cirrhosis, tuberculosis, congestive heart failure, hyperlipidemia and CKD (table 1).

    In general, 2-year and 5-year overall survival rates were statistically significantly different between the surgery-RT and surgery-alone groups, as follows: 65.6% versus 85.3%, and 48.4% versus 77.0%, respectively (p<0.0001). In addition, 2-year and 5-year distant-metastatic-free survival rates were also statistically significantly different between the two groups: 42.4% versus 86.1%, and 26.3% versus 78.1%, respectively (p<0.0001).

    The primary endpoint: risk level of hospitalised pneumonopathy (pneumonia/pneumonitis) occurrence

    Two observations supported a high incidence of pneumonia/pneumonitis occurrence in surgery-RT patients when compared with surgical-alone patients. First, we observed high incidences of hospitalised pneumonia/pneumonitis in surgery-RT patients, that is, per 1000 person-year at 2 years (200.2 vs 95.1, 2.11 folds) and at 5 years (151.2 vs 65.9, 2.29 folds; figure 1). Second, we found a low 2-year hospitalised pneumonia/pneumonitis-free survival rate in surgery-RT patients (69.0% vs 85.2%, p<0.0001; figure 2A). Data from all pneumonia/pneumonitis-free survival showed similar findings (figure 2B). However, in patients who were treated with RT, a higher estimated dose level wasn’t associated with a lower 2-year hospitalised pneumonia/pneumonitis-free survival (68.9% vs 68.6%, p=0.586). This may be due to a relatively low threshold dose (when compared with therapeutic dose) that potentially increases a risk of pneumonia/pneumonitis occurrence.58

    Figure 2
    Figure 2

    Kaplan-Meir estimates of pneumonia/pneumonitis-free survival between the surgery-plus-RT and surgery-alone groups: Panel A, hospitalised pneumonia/pneumonitis-free survival (p<0.0001): Panel B, all pneumonia/pneumonitis-free survival (p<0.0001).

    Multivariable analysis confirmed five independent risk factors for hospitalised pneumonia/pneumonitis occurrence

    As shown in table 2, multivariable analysis identified five independent risk factors for predicting hospitalised pneumonia/pneumonitis occurrence: irradiation (HR, 2.20; 95% CI, 1.93–2.51; p<0.0001), age >65 years (HR, 1.86; 95% CI, 1.60–2.16; p<0.0001), male gender (HR, 2.00; 95% CI, 1.72–2.32; p<0.0001), COPD (HR, 1.28; 95% CI, 1.12–1.46; p=0.0002) and CKD (HR, 1.41; 95% CI, 1.10–1.82; p=0.006; table 2 and figure 3A–D).

    Figure 3
    Figure 3

    Cumulative risk estimates of hospitalised pneumonia occurrence between the surgery-RT and surgery-alone groups, stratifying according to independent factors: Panel A, age; Panel B, gender; Panel C, COPD; Panel D, CKD.

    View this table:
    Table 2

    Adjusted hazards for hospitalised and all pneumonia/pneumonitis occurrence

    To further demarcate the risk levels of hospitalised pneumonia/pneumonitis occurrence, we performed simplified sensitivity analysis among three major independent factors: irradiation, age and gender (table 3). A risk-increasing trend was observed in eight stratified patient subgroups. Remarkably, a very high risk was observed in irradiated elderly males (HR, 9.22; 95% CI, 6.44–13.19; p<0.0001), when compared with non-irradiated younger females (reference =1). The analysed results were similar when the reference group was defined as ‘non-irradiated younger male’ or ‘irradiated younger female’. Intergroup p values in the above two conditions were both ranged between 0.01 and <0.0001.

    An unexpected finding

    Unexpectedly, we found a higher risk of hospitalised pneumonia/pneumonitis occurrence in younger irradiated-CKD patients (HR, 13.07; 95% CI, 5.71–29.94; p<0.0001) than that of elderly irradiated-CKD patients (HR, 4.82; 95% CI, 2.88–8.08; p<0.0001; table 4), This unexpected observation created a biological interest for further investigation.

    View this table:
    Table 3

    Estimated hazards for hospitalised and all pneumonia/pneumonitis: stratified by treatment groups, age and gender

    View this table:
    Table 4

    Estimated hazards for pneumonia-free and overall survival: stratified by treatment groups, CKD, and age

    Integer risk score analysis

    Furthermore, independent factors were used to construct a risk-predicting model, according to integer risk score (table 5).56 Three groups were classified: the high-risk group, patients with a score of >18; the medium-risk group, patients with a score of 13–17; and the low-risk group, patients with a score of <12. As shown in figure 4, this model works well. Remarkably, the highest risk of hospitalised pneumonia/pneumonitis was observed in irradiated elderly males with COPD and CKD (HR, 13.74; 95% CI, 6.61–28.53; p<0.0001), when compared with non-irradiated younger female patients without COPD and CKD (reference group, HR=1).

    View this table:
    Table 5

    Independent predictors for hospitalised pneumonia/pneumonitis occurrence

    Figure 4
    Figure 4

    Cumulative risk estimates of hospitalised pneumonia/pneumonitis occurrence according to regression-based risk grouping: the high-risk group, patients with a score of >18; the medium-risk group, patients with a score of 13–17; and the low-risk group, patients with a score of <12. Note that score is calculated and summed according to individual regression co-efficient (table 5), with respect to five independent factors (age, gender, COPD, CKD and irradiation).

    Discussion

    Main finding: a high risk of hospitalised pneumonopathy occurrence in irradiated lung cancer patients

    In irradiated lung cancer patients, radiotherapy has been reported to increase incidences of pneumonopathy, including infectious5 and non-infectious pneumonia,7 as well as pneumonitis.11 A common feature exists among these types of pneumonopathy. That is, all of them threatened a patient’s life when disease progression was noted to impair apatient’s lung function significantly. Thus, investigating adverse risk factors to identify high-risk patients is critical. However, population-based evidence is largely lacking in this issue.

    In the present study, three observations supported a high risk of hospitalised pneumonia/pneumonitis occurrence in postoperatively irradiated lung cancer patients when compared with that of non-irradiated patients: a higher incidence of hospitalised pneumonia/pneumonitis at 2 years (200.2 vs 95.1 per 1000 person-year); a lower rate of 2-year hospitalised pneumonia/pneumonitis-free survival, 69.0% vs 85.2% (p<0.0001; figure 2); and a higher adjusted HR of 2.20 (95% CI, 1.93–2.51; p<0.0001; table 2).

    Moreover, we observed a high risk in irradiated elderly male patients (HR, 9.22; 95% CI, 6.44–13.19; p<0.0001; table 3), especially in those with COPD and CKD (HR, 13.74; 95% CI, 6.61–28.53; p<0.0001). Integer risk score further stratified three risk groups (table 5 and figure 4). Aggressive clinical surveillance and pneumonia/pneumonitis prevention should be critically considered for high-risk patient populations.

    Biological reasoning: radiation-associated lung injury may further damage innate immune and then increase a risk of infectious pneumonia in irradiated lung cancer patients

    The present study generates a biological hypothesis: irradiation may further damage innate immune, induce more barrier defects, and then increase a risk of secondary infectious pneumonia occurrence in irradiated lung cancer patients, especially in those with COPD.

    Three reasons supported this hypothesis. First, several lines of evidence have been reported to support that irradiation may induce several forms of pathological pneumonopathy, such as post-irradiation organising pneumonia,7 8 acute pneumonitis and/or late fibrosis.28 34 59–61 These irradiation-induced pathological changes are able to damage resident lung cells, to disrupt local barriers and to disturb local immune of the irradiated lung.62 63 Thus, an increased risk of secondary infectious pneumonia is reasonable, as this phenomenon has been observed in irradiated nasopharyngeal cancer patients.64 In molecular biology, several genetic variants of irradiation-responsive genes (eg, polymorphisms of XRCC1, 65 P53, 66 ATM 66 and APEX1 65 67) and TGF-β168 have been reported to be as potential biomarkers or predictors in predicting radiation-associated pneumonitis and pneumonia. Thus, these genes might be involved in the underlying pathological processes. However, further in vitro and in vivo studies are required to validate their real roles.

    Second, a high incidence of radiation pneumonitis was observed in irradiated lung cancer patients with a comorbidity of COPD.31 69 70 Third, COPD itself induces barrier defects of the lung71 and increases a risk of secondary pneumonia occurrence,23 especially in those patients aged >65 years.72 73 Our results agreed with these observations. A high risk of hospitalised pneumonopathy (ie, pneumonia/pneumonitis) was found in irradiated lung cancer patients, especially in those with COPD (table 2 and figure 3C). Detailed biological mechanisms should be further investigated.

    Biology interesting: an increased risk of hospitalised pneumonia/pneumonitis occurrence in lung cancer patients with CKD

    Patients with CKD are at a high risk of encountering hospitalised pneumonia,24 74 even after a renal transplantation.75 On the other hand, very few studies reported an association of CKD with radiation pneumonitis. In the literature, we observed that the Renin-Angiotensin system may be contributed as a key factor to link CKD and radiation pneumonitis. First, CKD patients have been reported to demonstrate a relatively hyperactive Renin-Angiotensin system,76 which is considered as a risk factor of developing radiation pneumonitis.77 78 Second, inhibiting the Renin-Angiotensin system may reduce the development of symptomatic radiation pneumonitis.79 80 However, evidence in defining this issue is largely lacking. Therefore, by combined severe pneumonopathy as a whole, our data confirmed CKD increased a small but substantial risk of hospitalised pneumonia/pneumonitis occurrence in post-operative irradiated lung cancer patients (adjusted HR, 1.41; 95% CI, 1.10–1.82; p=0.006; table 2 and figure 3D), supporting a potential hazard effect of CKD in radiation-associated pneumonopathy.

    More interestingly, as shown in table 4, we observed an unexpectedly higher risk of hospitalised pneumonia/pneumonitis occurrence in younger irradiated-CKD patients (HR, 13.07; 95% CI, 5.71–29.94; p<0.0001) than that of elderly irradiated-CKD patients (HR, 4.82; 95% CI, 2.88–8.08; p<0.0001). This finding was similar with a prior observation.44 However, detailed biological mechanisms are largely unknown in this phenomenon. Further exploration should be warranted.

    A population-based surgical cohort is suitable to explore a risk level of pneumonia/pneumonitis occurrence in irradiated lung cancer patients

    As mentioned above and previously,36 to explore the risk level of pneumonia/pneumonitis in irradiated lung cancer patients, two reasons led us to select patients who were treated with surgery as the study population.48 81 82 First, resected lung cancer patients characterise ‘technically resectable’ tumours and a ‘medically operable’ physical status, minimising confounding effects.36 Second, resected lung cancer patients had a significant longer survival rate than that of un-resected patients, allowing a more likely observation of late events of pneumonia/pneumonitis.36 83

    Moreover, lung cancer itself and thoracic surgery have been reported as risk factors of pneumonia/pneumonitis occurrence.19 25–27 33 Thus, the present study identified lung cancer patients who were treated with surgery alone as a comparison cohort, as reported previously.36

    Study strength

    A population-based study has several advantages in conducting clinical research. For example, it is suitable to investigate clinical questions that are unethical or difficult to be answered by using randomised clinical trials.84 85 Moreover, a population-based study is recommended in exploring a rare-event association36 53 86 87 and in demarcating what is actually achieved in the real medical world.36 84 85 88 Thus, we used a population-based design to explore a risk level of hospitalised pneumonopathy in irradiated lung cancer patients, being similar with our previous report.36

    Next, to overcome potential limitations of regression analysis,41 54 we conducted a propensity score match to balance study groups before statistical analysis.54 84 89 After an effective match, we created a near head-to-head condition before statistical analysis (table 1)46.This approach led to a more clear inference in answering our study question.

    Finally, to decrease unmeasured confounding effects, we conducted a simplified sensitivity analysis according to independent risk factors.36 55 90 Moreover, we used an integer risk score to further stratify high-risk patients.56 As shown in figure 4, this risk-stratified model worked well.

    Study limitations

    We declared several limitations of the present study, as reported previously.36 For example, unobserved variables do exist, such as smoking habits, infectious pathogens, the dialysis period and cancer stage. For minimising effects of this limitation, we used several strategies.36 55 First, we used ‘COPD’ to represent ‘smoking habits’ at least partly.36 55 91 Second, we applied ‘charge code of radiotherapy’ to estimate ‘radiation doses'.36 Third, we excluded ‘patients who were treated with chemotherapy’ to narrow down the study population and to decrease potentially confounding effects.36 47 48 Fourth, to further reduce potential bias, though an extensive sensitivity analysis cannot be done because of our relatively small sample size,36 55 we still applied a simplified sensitivity analysis that stratified by independent factors.36

    However, despite the above efforts, intrinsic limitations of the present study cannot be fully eliminated. Thus, interpreting the present data should be done carefully as additional studies are required.

    Conclusion

    A high incidence of severe pneumonopathy, that is, pneumonia and/or pneumonitis that required in-patient care, was observed in postoperatively irradiated lung cancer patients, especially in elderly males with COPD and CKD. For these patients, close clinical surveillance and aggressive prevention for pneumonia/pneumonitis should be critically considered. Further bench studies are encouraged to explore underpinning biological mechanisms.

    Acknowledgments

    This study utilises research data from the Taiwan National Health Insurance Research Database provided by the Bureau of Taiwan National Health Insurance (TNHI), Department of Health and managed by National Health Research Institutes (registry number 99029). Results were validated by using another independent dataset (registry number 100266; data not shown). The interpretation and conclusions contained herein are not those of the Bureau of National Health Insurance, Department of Health or National Health Research Institutes.

    References

    1. 1.↵
      2. Torre LA ,
      3. Sauer AM ,
      4. Chen MS , et al
      . Cancer statistics for Asian Americans, Native Hawaiians, and Pacific Islanders, 2016: Converging incidence in males and females. CA Cancer J Clin 2016;66:182–202.doi:10.3322/caac.21335
      OpenUrl
    2. 2.↵
      2. Siegel RL ,
      3. Miller KD ,
      4. Jemal A , et al
      . Cancer statistics, 2016. CA Cancer J Clin  2016;66:7–30.doi:10.3322/caac.21332
      OpenUrlCrossRefPubMed
    3. 3.↵
      2. Torre LA ,
      3. Siegel RL ,
      4. Jemal A , et al
      . Lung cancer statistics. Adv Exp Med Biol 2016;893:1–19.
      OpenUrlCrossRefPubMed
    4. 4.↵
      NCCN.org. Clinical practice guidelines in oncology: non-small cell lung cancer. Version 4. (NCCN Guidelines™). 2016 http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
    5. 5.↵
      2. Maimon N ,
      3. Barski L ,
      4. Sion-Vardy N , et al
      . A man with interstitial pneumonia and pancytopenia during radiotherapy. Chest 2004;126:1368–71.doi:10.1378/chest.126.4.1368
      OpenUrlCrossRefPubMed
    6. 6.↵
      2. Reckzeh B ,
      3. Merte H ,
      4. Pflüger KH , et al
      . Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer. J Clin Oncol 1996;14:1071–6.doi:10.1200/JCO.1996.14.4.1071
      OpenUrlAbstract/FREE Full Text
    7. 7.↵
      2. Ochiai S ,
      3. Nomoto Y ,
      4. Yamashita Y , et al
      . Radiation-induced organizing pneumonia after stereotactic body radiotherapy for lung tumor. J Radiat Res 2015;56:904–11.doi:10.1093/jrr/rrv049
      OpenUrlCrossRefPubMed
    8. 8.↵
      2. Oie Y ,
      3. Saito Y ,
      4. Kato M , et al
      . Relationship between radiation pneumonitis and organizing pneumonia after radiotherapy for breast cancer. Radiat Oncol 2013;8:56.doi:10.1186/1748-717X-8-56
      OpenUrlCrossRefPubMed
    9. 9.↵
      2. Epler GR
      . Post-breast cancer radiotherapy bronchiolitis obliterans organizing pneumonia. Expert Rev Respir Med 2013;7:109–12.doi:10.1586/ers.13.1
      OpenUrlCrossRefPubMed
    10. 10.↵
      2. Murai T ,
      3. Shibamoto Y ,
      4. Nishiyama T , et al
      . Organizing pneumonia after stereotactic ablative radiotherapy of the lung. Radiat Oncol 2012;7:123.doi:10.1186/1748-717X-7-123
      OpenUrlCrossRefPubMed
    11. 11.↵
      2. Leprieur EG ,
      3. Fernandez D ,
      4. Chatellier G , et al
      . Acute radiation pneumonitis after conformational radiotherapy for nonsmall cell lung cancer: clinical, dosimetric, and associated-treatment risk factors. J Cancer Res Ther 2013;9:447–51.doi:10.4103/0973-1482.119339
      OpenUrl
    12. 12.↵
      2. Arrieta O ,
      3. Gallardo-Rincón D ,
      4. Villarreal-Garza C , et al
      . High frequency of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent radiotherapy and gemcitabine after induction with gemcitabine and carboplatin. J Thorac Oncol 2009;4:845–52.doi:10.1097/JTO.0b013e3181a97e17
      OpenUrlCrossRefPubMed
    13. 13.↵
      2. Yamaguchi S ,
      3. Ohguri T ,
      4. Matsuki Y , et al
      . Radiotherapy for thoracic tumors: association between subclinical interstitial lung disease and fatal radiation pneumonitis. Int J Clin Oncol 2015;20.doi:10.1007/s10147-014-0679-1
    14. 14.↵
      2. Tokuda Y ,
      3. Takigawa N ,
      4. Kozuki T , et al
      . Long-term follow-up of phase II trial of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer. Acta Oncol 2012;51:537–40.doi:10.3109/0284186X.2011.631580
      OpenUrlPubMed
    15. 15.↵
      2. Yirmibesoglu E ,
      3. Higginson DS ,
      4. Fayda M , et al
      . Challenges scoring radiation pneumonitis in patients irradiated for lung cancer. Lung Cancer 2012;76:350–3.doi:10.1016/j.lungcan.2011.11.025
      OpenUrlPubMed
    16. 16.↵
      2. Phillips TL ,
      3. Hoppe RT ,
      4. Roach M
      . Leibel and Phillips Textbook of Radiation Oncology. 3rd ed. Philadelphia: Saunders, an imprint of Elsevier Inc, 2010.
    17. 17.↵
      2. Kocak Z ,
      3. Evans ES ,
      4. Zhou SM , et al
      . Challenges in defining radiation pneumonitis in patients with lung cancer. Int J Radiat Oncol Biol Phys 2005;62:635–8.doi:10.1016/j.ijrobp.2004.12.023
      OpenUrlCrossRefPubMed
    18. 18.↵
      2. Anderson EJ
      . Respiratory infections. Cancer Treat Res 2014;161:203–36.doi:10.1007/978-3-319-04220-6_7
      OpenUrl
    19. 19.↵
      2. Akinosoglou KS ,
      3. Karkoulias K ,
      4. Marangos M
      . Infectious complications in patients with lung cancer. Eur Rev Med Pharmacol Sci 2013;17:8–18.
      OpenUrlPubMed
    20. 20.↵
      2. Robnett TJ ,
      3. Machtay M ,
      4. Vines EF , et al
      . Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 2000;48:89–94.doi:10.1016/S0360-3016(00)00648-9
      OpenUrlPubMedWeb of Science
    21. 21.↵
      2. Khalil AA ,
      3. Hoffmann L ,
      4. Moeller DS , et al
      . New dose constraint reduces radiation-induced fatal pneumonitis in locally advanced non-small cell lung cancer patients treated with intensity-modulated radiotherapy. Acta Oncol 2015;54:1343–9.doi:10.3109/0284186X.2015.1061216
      OpenUrl
    22. 22.↵
      2. Welte T
      . Risk factors and severity scores in hospitalized patients with community-acquired pneumonia: prediction of severity and mortality. Eur J Clin Microbiol Infect Dis 2012;31:33–47.doi:10.1007/s10096-011-1272-4
      OpenUrlPubMed
    23. 23.↵
      2. Yamada Y ,
      3. Sekine Y ,
      4. Suzuki H , et al
      . Trends of bacterial colonisation and the risk of postoperative pneumonia in lung cancer patients with chronic obstructive pulmonary disease. Eur J Cardiothorac Surg 2010;37:752–7.doi:10.1016/j.ejcts.2009.05.039
      OpenUrlCrossRefPubMed
    24. 24.↵
      2. Viasus D ,
      3. Garcia-Vidal C ,
      4. Cruzado JM , et al
      . Epidemiology, clinical features and outcomes of pneumonia in patients with chronic kidney disease. Nephrol Dial Transplant 2011;26:2899–906.doi:10.1093/ndt/gfq798
      OpenUrlCrossRefPubMedWeb of Science
    25. 25.↵
      2. Lee JY ,
      3. Jin SM ,
      4. Lee CH , et al
      . Risk factors of postoperative pneumonia after lung cancer surgery. J Korean Med Sci 2011;26:979–84.doi:10.3346/jkms.2011.26.8.979
      OpenUrlCrossRefPubMed
    26. 26.↵
      2. Pool KL ,
      3. Munden RF ,
      4. Vaporciyan A , et al
      . Radiographic imaging features of thoracic complications after pneumonectomy in oncologic patients. Eur J Radiol 2012;81:165–72.doi:10.1016/j.ejrad.2010.08.040
      OpenUrlCrossRefPubMed
    27. 27.↵
      2. Takeda S ,
      3. Maeda H ,
      4. Sawabata N , et al
      . Clinical impact of interstitial pneumonia following surgery for lung cancer. Thorac Cardiovasc Surg 2006;54:268–72.doi:10.1055/s-2005-873068
      OpenUrlPubMed
    28. 28.↵
      2. Minami-Shimmyo Y ,
      3. Ohe Y ,
      4. Yamamoto S , et al
      . Risk factors for treatment-related death associated with chemotherapy and thoracic radiotherapy for lung cancer. J Thorac Oncol 2012;7:177–82.doi:10.1097/JTO.0b013e31823c4c07
      OpenUrlCrossRefPubMed
    29. 29.↵
      2. Dang J ,
      3. Li G ,
      4. Zang S , et al
      . Risk and predictors for early radiation pneumonitis in patients with stage III non-small cell lung cancer treated with concurrent or sequential chemoradiotherapy. Radiat Oncol 2014;9:172.doi:10.1186/1748-717X-9-172
      OpenUrlCrossRefPubMed
    30. 30.↵
      2. Dang J ,
      3. Li G ,
      4. Ma L , et al
      . Predictors of grade ≥ 2 and grade ≥ 3 radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with three-dimensional conformal radiotherapy. Acta Oncol 2013;52:1175–80.doi:10.3109/0284186X.2012.747696
      OpenUrlPubMed
    31. 31.↵
      2. Inoue T ,
      3. Shiomi H ,
      4. Oh RJ
      . Stereotactic body radiotherapy for Stage I lung cancer with chronic obstructive pulmonary disease: special reference to survival and radiation-induced pneumonitis. J Radiat Res 2015;56:727–34.doi:10.1093/jrr/rrv019
      OpenUrlCrossRefPubMed
    32. 32.↵
      2. Zhang XJ ,
      3. Sun JG ,
      4. Sun J , et al
      . Prediction of radiation pneumonitis in lung cancer patients: a systematic review. J Cancer Res Clin Oncol 2012;138:2103–16.doi:10.1007/s00432-012-1284-1
      OpenUrlCrossRefPubMed
    33. 33.↵
      2. Dang J ,
      3. Li G ,
      4. Zang S , et al
      . Comparison of risk and predictors for early radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with radiotherapy with or without surgery. Lung Cancer 2014;86:329–33.doi:10.1016/j.lungcan.2014.10.005
      OpenUrl
    34. 34.↵
      2. Parashar B ,
      3. Edwards A ,
      4. Mehta R , et al
      . Chemotherapy significantly increases the risk of radiation pneumonitis in radiation therapy of advanced lung cancer. Am J Clin Oncol 2011;34:160–4.doi:10.1097/COC.0b013e3181d6b40f
      OpenUrlPubMed
    35. 35.↵
      2. Wei KC ,
      3. Lin HY ,
      4. Hung SK , et al
      . Leukemia risk after cardiac fluoroscopic interventions stratified by procedure number, exposure latent time, and sex: a nationwide population-based case-control study. Medicine 2016;95:e2953.doi:10.1097/MD.0000000000002953
    36. 36.↵
      2. Hung SK ,
      3. Lee MS ,
      4. Chiou WY , et al
      . High incidence of ischemic stroke occurrence in irradiated lung cancer patients: a population-based surgical cohort study. PLoS One 2014;9:e94377.doi:10.1371/journal.pone.0094377
    37. 37.↵
      2. Chiou WY ,
      3. Hung SK ,
      4. Lai CL , et al
      . Effect of 23-valent pneumococcal polysaccharide vaccine inoculated during anti-cancer treatment period in elderly lung cancer patients on community-acquired pneumonia hospitalization: a nationwide population-based cohort study. Medicine 2015;94:e1022.doi:10.1097/MD.0000000000001022
    38. 38.↵
      2. Chen PC ,
      3. Muo CH ,
      4. Lee YT , et al
      . Lung cancer and incidence of stroke: a population-based cohort study. Stroke 2011;42:3034–9.doi:10.1161/STROKEAHA.111.615534
      OpenUrlAbstract/FREE Full Text
    39. 39.↵
      2. Tsai SJ ,
      3. Huang YS ,
      4. Tung CH , et al
      . Increased risk of ischemic stroke in cervical cancer patients: a nationwide population-based study. Radiat Oncol 2013;8:41.doi:10.1186/1748-717X-8-41
      OpenUrlCrossRefPubMed
    40. 40.↵
      2. Kalincik T ,
      3. Horakova D ,
      4. Spelman T , et al
      . Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. Ann Neurol 2015;77:425–35.doi:10.1002/ana.24339
      OpenUrlCrossRefPubMed
    41. 41.↵
      2. Katz MH
      . Evaluating clinical and public health interventions: a practical guide to study design and statistics. Cambridge: Cambridge University Press, 2010.
    42. 42.↵
      2. Palmu AA ,
      3. Saukkoriipi A ,
      4. Snellman M , et al
      . Incidence and etiology of community-acquired pneumonia in the elderly in a prospective population-based study. Scand J Infect Dis 2014;46:250–9.doi:10.3109/00365548.2013.876509
      OpenUrlCrossRef
    43. 43.↵
      2. Ishigami K ,
      3. Okuro M ,
      4. Koizumi Y , et al
      . Association of severe hypertension with pneumonia in elderly patients with acute ischemic stroke. Hypertens Res 2012;35:648–53.doi:10.1038/hr.2012.7
      OpenUrlCrossRefPubMed
    44. 44.↵
      2. James MT ,
      3. Quan H ,
      4. Tonelli M , et al
      . CKD and risk of hospitalization and death with pneumonia. Am J Kidney Dis 2009;54:24–32.doi:10.1053/j.ajkd.2009.04.005
      OpenUrlCrossRefPubMedWeb of Science
    45. 45.↵
      2. Austin PC
      . Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 2011;10:150–61.doi:10.1002/pst.433
      OpenUrlCrossRefPubMed
    46. 46.↵
      2. Nagami Y ,
      3. Shiba M ,
      4. Tominaga K , et al
      . Locoregional steroid injection prevents stricture formation after endoscopic submucosal dissection for esophageal cancer: a propensity score matching analysis. Surg Endosc 2016;30:1441–9.doi:10.1007/s00464-015-4348-x
      OpenUrl
    47. 47.↵
      2. Greene FL
      . AJCC cancer staging atlas. 6 edn. New York, NY: Springer, 2006.
    48. 48.↵
      NCCN.org. Clinical Practice Guidelines in Oncology: Non-small cell lung cancer. Version 3. (NCCN Guidelines™). 2014 http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
    49. 49.↵
      2. Rami-Porta R ,
      3. Crowley JJ ,
      4. Goldstraw P
      . The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg 2009;15:4–9.
      OpenUrlPubMedWeb of Science
    50. 50.↵
      Institutes TNHR. Taiwan cancer center accreditation. 2014 http://www.nhri.org.tw/nhri_org/ca/accredit/index.htm (accessed 12 Mar 2014).
    51. 51.↵
      2. Monge V ,
      3. González A
      . Hospital admissions for pneumonia in Spain. Infection 2001;29:3–6.doi:10.1007/s15010-001-0024-2
      OpenUrlCrossRefPubMedWeb of Science
    52. 52.↵
      2. Schulz KF
      . CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2010;152:726–32.doi:10.7326/0003-4819-152-11-201006010-00232
      OpenUrlCrossRefPubMedWeb of Science
    53. 53.↵
      2. von Elm E ,
      3. Altman DG ,
      4. Egger M , et al
      . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 2007;4:e296.doi:10.1371/journal.pmed.0040296
      OpenUrlCrossRefPubMed
    54. 54.↵
      2. Steyerberg EW
      . Clinical prediction models: a practical approach to development, validation, and updating. New York; London: Springer, 2009.
    55. 55.↵
      2. Tsan YT ,
      3. Lee CH ,
      4. Ho WC , et al
      . Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. J Clin Oncol 2013;31:1514–21.doi:10.1200/JCO.2012.44.6831
      OpenUrlAbstract/FREE Full Text
    56. 56.↵
      2. Lee MH ,
      3. Yang HI ,
      4. Liu J , et al
      . Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology 2013;58:546–54.doi:10.1002/hep.26385
      OpenUrlCrossRefPubMedWeb of Science
    57. 57.↵
      2. Sullivan LM ,
      3. Massaro JM ,
      4. D’Agostino RB
      . Presentation of multivariate data for clinical use: The Framingham Study risk score functions. Stat Med 2004;23:1631–60.doi:10.1002/sim.1742
      OpenUrlCrossRefPubMedWeb of Science
    58. 58.↵
      2. Trodella L ,
      3. Ramella S ,
      4. Salvi G , et al
      . Dose and volume as predictive factors of pulmonary toxicity. Rays 2005;30:175–80.
      OpenUrlPubMed
    59. 59.↵
      2. Werner-Wasik M ,
      3. Paulus R ,
      4. Curran WJ , et al
      . Acute esophagitis and late lung toxicity in concurrent chemoradiotherapy trials in patients with locally advanced non-small-cell lung cancer: analysis of the radiation therapy oncology group (RTOG) database. Clin Lung Cancer 2011;12:245–51.doi:10.1016/j.cllc.2011.03.026
      OpenUrlCrossRefPubMedWeb of Science
    60. 60.↵
      2. Palma DA ,
      3. Senan S ,
      4. Tsujino K , et al
      . Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 2013;85:444–50.doi:10.1016/j.ijrobp.2012.04.043
      OpenUrlCrossRefPubMed
    61. 61.↵
      2. Omer H ,
      3. Sulieman A ,
      4. Alzimami K
      . Risks of lung fibrosis and pneumonitis after postmastectomy electron radiotherapy. Radiat Prot Dosimetry 2015;165:499–502.doi:10.1093/rpd/ncv111
      OpenUrlCrossRefPubMed
    62. 62.↵
      2. Tsoutsou PG
      . The interplay between radiation and the immune system in the field of post-radical pneumonitis and fibrosis and why it is important to understand it. Expert Opin Pharmacother 2014;15:1781–3.doi:10.1517/14656566.2014.938049
      OpenUrl
    63. 63.↵
      2. Cappuccini F ,
      3. Eldh T ,
      4. Bruder D , et al
      . New insights into the molecular pathology of radiation-induced pneumopathy. Radiother Oncol 2011;101:86–92.doi:10.1016/j.radonc.2011.05.064
      OpenUrlCrossRefPubMed
    64. 64.↵
      2. Yen TT ,
      3. Lin CH ,
      4. Jiang RS , et al
      . Incidence of late-onset pneumonia in patients after treatment with radiotherapy for nasopharyngeal carcinoma: a nationwide population-based study. Head Neck 2015;37:1756–61.doi:10.1002/hed.23827
      OpenUrl
    65. 65.↵
      2. Yin M ,
      3. Liao Z ,
      4. Liu Z , et al
      . Functional polymorphisms of base excision repair genes XRCC1 and APEX1 predict risk of radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy. Int J Radiat Oncol Biol Phys 2011;81:e67–73.doi:10.1016/j.ijrobp.2010.11.079
      OpenUrlCrossRefPubMed
    66. 66.↵
      2. Yang M ,
      3. Zhang L ,
      4. Bi N , et al
      . Association of P53 and ATM polymorphisms with risk of radiation-induced pneumonitis in lung cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 2011;79:1402–7.doi:10.1016/j.ijrobp.2009.12.042
      OpenUrlCrossRefPubMed
    67. 67.↵
      2. Li H ,
      3. Liu G ,
      4. Xia L , et al
      . A polymorphism in the DNA repair domain of APEX1 is associated with the radiation-induced pneumonitis risk among lung cancer patients after radiotherapy. Br J Radiol 2014;87:20140093.doi:10.1259/bjr.20140093
      OpenUrlCrossRefPubMed
    68. 68.↵
      2. He J ,
      3. Deng L ,
      4. Na F , et al
      . The association between TGF-β1 polymorphisms and radiation pneumonia in lung cancer patients treated with definitive radiotherapy: a meta-analysis. PLoS One 2014;9:e91100.doi:10.1371/journal.pone.0091100
    69. 69.↵
      2. Kimura T ,
      3. Togami T ,
      4. Takashima H , et al
      . Radiation pneumonitis in patients with lung and mediastinal tumours: a retrospective study of risk factors focused on pulmonary emphysema. Br J Radiol 2012;85:135–41.doi:10.1259/bjr/32629867
      OpenUrlAbstract/FREE Full Text
    70. 70.↵
      2. Rancati T ,
      3. Ceresoli GL ,
      4. Gagliardi G , et al
      . Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study. Radiother Oncol 2003;67:275–83.doi:10.1016/S0167-8140(03)00119-1
      OpenUrlCrossRefPubMedWeb of Science
    71. 71.↵
      2. Roy MG ,
      3. Livraghi-Butrico A ,
      4. Fletcher AA , et al
      . Muc5b is required for airway defence. Nature 2014;505:412–6.doi:10.1038/nature12807
      OpenUrlCrossRefPubMedWeb of Science
    72. 72.↵
      2. Müllerova H ,
      3. Chigbo C ,
      4. Hagan GW , et al
      . The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med 2012;106:1124–33.doi:10.1016/j.rmed.2012.04.008
      OpenUrlCrossRefPubMed
    73. 73.↵
      2. Ryan M ,
      3. Suaya JA ,
      4. Chapman JD , et al
      . Incidence and cost of pneumonia in older adults with COPD in the United States. PLoS One 2013;8:e75887.doi:10.1371/journal.pone.0075887
    74. 74.↵
      2. Chou CY ,
      3. Wang SM ,
      4. Liang CC , et al
      . Risk of pneumonia among patients with chronic kidney disease in outpatient and inpatient settings: a nationwide population-based study. Medicine 2014;93:e174.doi:10.1097/MD.0000000000000174
    75. 75.↵
      2. Nielsen LH ,
      3. Jensen-Fangel S ,
      4. Jespersen B , et al
      . Risk and prognosis of hospitalization for pneumonia among individuals with and without functioning renal transplants in Denmark: a population-based study. Clin Infect Dis 2012;55:679–86.doi:10.1093/cid/cis488
      OpenUrlCrossRefPubMed
    76. 76.↵
      2. Santos PC ,
      3. Krieger JE ,
      4. Pereira AC
      . Renin-Angiotensin system, hypertension, and chronic kidney disease: pharmacogenetic implications. J Pharmacol Sci 2012;120:77–88.doi:10.1254/jphs.12R03CR
      OpenUrlCrossRefPubMed
    77. 77.↵
      2. Mahmood J ,
      3. Jelveh S ,
      4. Zaidi A , et al
      . Targeting the Renin-Angiotensin system combined with an antioxidant is highly effective in mitigating radiation-induced lung damage. Int J Radiat Oncol Biol Phys 2014;89:722–8.doi:10.1016/j.ijrobp.2014.03.048
      OpenUrlCrossRefPubMed
    78. 78.↵
      2. Ghosh SN ,
      3. Zhang R ,
      4. Fish BL , et al
      . Renin-Angiotensin system suppression mitigates experimental radiation pneumonitis. Int J Radiat Oncol Biol Phys 2009;75:1528–36.doi:10.1016/j.ijrobp.2009.07.1743
      OpenUrlCrossRefPubMed
    79. 79.↵
      2. Bracci S ,
      3. Valeriani M ,
      4. Agolli L , et al
      . Renin-Angiotensin system Inhibitors might help to reduce the development of symptomatic radiation pneumonitis after stereotactic body radiotherapy for lung cancer. Clin Lung Cancer 2016;17:189–97.doi:10.1016/j.cllc.2015.08.007
      OpenUrl
    80. 80.↵
      2. Bracci S ,
      3. Valeriani M ,
      4. Agolli L , et al
      . Renin-Angiotensin system inhibitors might help to reduce the development of symptomatic radiation pneumonitis after stereotactic body radiotherapy for lung cancer. Clin Lung Cancer 2016;17:189–97.doi:10.1016/j.cllc.2015.08.007
      OpenUrl
    81. 81.↵
      2. Trodella L ,
      3. Granone P ,
      4. Valente S , et al
      . Adjuvant radiotherapy in non-small cell lung cancer with pathological stage I: definitive results of a phase III randomized trial. Radiother Oncol 2002;62:11–19.doi:10.1016/S0167-8140(01)00478-9
      OpenUrlCrossRefPubMedWeb of Science
    82. 82.↵
      2. Granone P ,
      3. Trodella L ,
      4. Margaritora S , et al
      . Radiotherapy versus follow-up in the treatment of pathological stage Ia and Ib non-small cell lung cancer. Early stopped analysis of a randomized controlled study. Eur J Cardiothorac Surg 2000;18:418–24.doi:10.1016/S1010-7940(00)00539-X
      OpenUrlCrossRefPubMed
    83. 83.↵
      2. Hall EJ ,
      3. Giaccia AJ
      . Radiobiology for the radiologist. 7th edn. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2012.
    84. 84.↵
      2. Rosenbaum PR
      . Design of observational studies. New York; London: Springer, 2010.
    85. 85.↵
      2. Maruyama K ,
      3. Kawahara N ,
      4. Shin M , et al
      . The risk of hemorrhage after radiosurgery for cerebral arteriovenous malformations. N Engl J Med 2005;352:146–53.doi:10.1056/NEJMoa040907
      OpenUrlCrossRefPubMedWeb of Science
    86. 86.↵
      2. Lin HW ,
      3. Tu YY ,
      4. Lin SY , et al
      . Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study. Lancet Oncol 2011;12:900–4.doi:10.1016/S1470-2045(11)70165-6
      OpenUrlCrossRefPubMedWeb of Science
    87. 87.↵
      2. Lee CC ,
      3. Ho HC ,
      4. Hsiao SH , et al
      . Infectious complications in head and neck cancer patients treated with cetuximab: propensity score and instrumental variable analysis. PLoS One 2012;7:e50163.doi:10.1371/journal.pone.0050163
    88. 88.↵
      2. Owonikoko TK ,
      3. Ragin C ,
      4. Chen Z , et al
      . Real-world effectiveness of systemic agents approved for advanced non-small cell lung cancer: a SEER-Medicare analysis. Oncologist 2013;18:600–10.doi:10.1634/theoncologist.2012-0480
      OpenUrlAbstract/FREE Full Text
    89. 89.↵
      2. Choudhury G ,
      3. Mandal P ,
      4. Singanayagam A , et al
      . Seven-day antibiotic courses have similar efficacy to prolonged courses in severe community-acquired pneumonia–a propensity-adjusted analysis. Clin Microbiol Infect 2011;17:1852–8.doi:10.1111/j.1469-0691.2011.03542.x
      OpenUrlCrossRefPubMed
    90. 90.↵
      2. VanderWeele TJ
      . Unmeasured confounding and hazard scales: sensitivity analysis for total, direct, and indirect effects. Eur J Epidemiol 2013;28:113–7.doi:10.1007/s10654-013-9770-6
      OpenUrlCrossRefPubMed
    91. 91.↵
      2. Stang P ,
      3. Lydick E ,
      4. Silberman C , et al
      . The prevalence of COPD: using smoking rates to estimate disease frequency in the general population. Chest 2000;117(5 Suppl 2):354S–9.
      OpenUrlCrossRefPubMedWeb of Science

    Footnotes

    • Contributors Conception or design (S-KH; Y-CC; M-SL; W-YC; C-LL; D-WL; N-CC; S-CL; Y-CL; MWYC; H-YL); or data acquisition (L-CC; L-WH), data analysis (F-CH; S-JT), or data interpretation (H-YL). Drafting (S-KH; S-JT) or revising the work (L-CC; L-WH; H-YL). Final approval (H-YL). Co-first authors: S-KH and S-JT contributed equally.

    • Funding The present study is supported by several research grants of our institute, that is, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation (grant number: DTCRD100[2]-I-14 and DTCRD101-E-18). The funding source fully supported requirement of the present work but did not interact with any of the research process, for example, design and interpretation.

    • Competing interests None declared.

    • Ethics approval The Institution Review Board (IRB) of the Buddhist Dalin Tzu Chi Hospital (approved number, B10001019)

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Data sharing statement All data were reported; no additional data are available.